STUDY PROTOCOL

Comparison of efficacy and safety of complementary and alternative therapies for essential hypertension with anxiety or depression disorder

Xueyan Han1, Xinxin Liu1, Fengxing Zhong2, Yiguo Wang2, Qiming Zhang1,2

1 Department of First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China, 2 Department of Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China

☯ These authors contributed equally to this work.

* zhang_917@126.com

Abstract

Background

Essential hypertension (EH) with anxiety or depression belongs to the category of psychocardiology. Hypertension is closely related to anxiety and depression. The adverse reactions of Western medicine are apparent and the compliance is poor. Supplementary and replacement therapies have accumulated rich experience in clinical practices, which can reduce side effects and improve clinical efficacy. This study intends to use the Bayesian network meta-analysis (NMA) analysis method for the first time to gather randomized controlled trials (RCTs) related to complementary and alternative therapies in the treatment of hypertension with anxiety or depression disorder and rank efficacy and safety, to provide a reference basis for the treatment of hypertension with anxiety or depression disorder.

Methods

All randomized controlled trials (RCTs) and registered and ongoing trials of Chinese and English databases, related to supplementation and replacement therapies of EH with anxiety or depression disorder, published from initial state to February 2021, will be collected in the form of computer retrieval. Two researchers will independently screen the literature, extracting data, assessing bias risk, and evaluating heterogeneity. We will use software WinBUGS 1.4.3 and Stata 16.0 for pairwise meta-analysis and NMA to comprehensively evaluate various interventions. The quality of evidence will be evaluated through the Grading of Recommendations Assessment, Development and Evaluation (GRADE).

Results

This NMA will comprehensively compare and rank the efficacy and safety of a series of complementary and alternative therapies in treating EH with anxiety or depression disorder.

Citation: Han X, Liu X, Zhong F, Wang Y, Zhang Q (2021) Comparison of efficacy and safety of complementary and alternative therapies for essential hypertension with anxiety or depression disorder. PLoS ONE 16(7): e0254699. https://doi.org/10.1371/journal.pone.0254699

Editor: Ismaeel Yunusa, University of South Carolina College of Pharmacy, UNITED STATES

Published: July 16, 2021

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: https://doi.org/10.1371/journal.pone.0254699

Copyright: © 2021 Han et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study is supported by Key R & D Program of the People’s Republic of China (2019YFC1711700). QZ received the award. URL=http://www.cncbd.org.cn/. The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
**Conclusion**

Supplementary and replacement therapies have accumulated rich experience of clinical practices in improving EH with anxiety or depression disorder. We expect that this NMA will guide practice and research by providing reliable evidence of evidence-based medicine for the treatment of EH with anxiety or depression disorder.

**Protocol registration number**

INPLASY202120068.

**Introduction**

Psycho-cardiology, which was put forward by James W. Jefferson for the first time [1], mainly studies the relationship between psychological diseases and cardiovascular diseases. Patients with cardiovascular diseases are often associated with anxiety or depression disorder, while hypertension is more likely to occur depression or anxiety among the common and frequently-occurring cardiovascular diseases.

In recent years, the prevalence of essential hypertension (EH) in China has increased. Hypertension is a primary risk factor for high morbidity and mortality of cardiovascular and cerebrovascular diseases worldwide. The World Health Organization has reported that 54% of stroke and 47% of ischemic heart disease are direct consequences of hypertension [2]. Although the epidemiological association between hypertension and cardiovascular disease morbidity/mortality is well known, and there is sufficient evidence to justify antihypertensive treatment, blood pressure (BP) is still not fully controlled. The reason may be the neglect of the intervention of psychological factors. Studies have shown that anxiety and depression are recognized risk factors for the development of EH, which augment the risk of death of cardiovascular disease, especially hypertension, by 4 times [3, 4].

Hypertension is closely related to anxiety and depression [5]. The incidence of hypertension complicated with anxiety and depression is 15–50% [6]. The incidence of depression in patients with hypertension is higher than that in patients with normal BP [7], and about 11.6% of middle-aged and elderly patients with hypertension are complicated with anxiety disorder [8]. Cohen et al. [9] have shown that anxiety can change the circadian rhythm of BP, leading to nocturnal hypertension and morning hypertension. Kayano et al. [10] after monitoring the ambulatory BP of 120 patients with hypertension, it was found that the night and early morning BP of patients with anxiety was higher than patients without anxiety, and the anxiety group was more likely to have anti-dipper BP. A meta-analysis included 9 related articles involving 22367 subjects with an average follow-up period of 9.6 years [11]. The results showed that depressive patients had a 1.42-fold higher risk of developing hypertension than non-depressive patients after adjusting for other risk factors. Depression can lead to elevated BP and then develop into systolic hypertension [12].

The mechanism of anxiety and depression leading to the increase of BP is roughly in 3 aspects. First, anxiety can affect the vascular endothelial function by activating the sympathetic nerve, causing the vascular endothelium to release vasoactive substances out of balance and affect the regulation of BP [5, 13]. Secondly, anxiety and depression can activate the Hypothalamic-Pituitary-Adrenal (HPA) axis system, promoting the secretion of glucocorticoids, improving the sensitivity of vascular smooth muscle to catecholamines, and promote the occurrence and progression of hypertension [14, 15]. Finally, anxiety and depression can...
activate the Renin-Angiotensin-Aldosterone System (RAAS), which leads to an increase in BP [16].

EH with anxiety or depression belongs to the category of psycho-cardiology. In terms of treatment, we should not only treat hypertension but also pay more attention to psychological diseases in order to achieve an excellent antihypertensive effect. Western medicine is often combined with anti-anxiety drugs or antidepressants. Although the anxiety and depression of patients are alleviated to some extent, many adverse reactions such as respiratory inhibition, mental fatigue, addiction, gastrointestinal reactions and so on are bad for the quality of life of patients. Another significant problem in treating anti-anxiety drugs or antidepressants is poor compliance, with about 50% of patients discontinuing prescription drugs in the first month of medication [17]. Studies have shown that tricyclic antidepressants and antidepressants that lower adrenaline and serotonin may lead to grade 1 hypertension in patients [18]. Supplementary and replacement therapies have accumulated rich experience in clinical practices, which can reduce side effects and improve clinical efficacy. Yoga, Tai Chi and Qigong are recognized as the complementary approaches for patients with anxiety or depression to improve sleep quality and reduce blood pressure [19]. Some studies have proved that yoga, slow walking, swimming and cycling can effectively relieve symptoms of anxiety and depression [20]. The modified Da Chaihu decoction was beneficial for hypertensive patients with anxiety in reducing BP [21]. Brief mindfulness meditation could significantly reduce anxiety symptoms and lower systolic blood pressure of Chinese nursing students [22].

The network meta-analysis (NMA) can be used to compare three or more interventions simultaneously, and can provide the probability of choosing the best intervention. This study intends to use the Bayesian network meta-analysis (NMA) analysis method for the first time to gather randomized controlled trials (RCTs) related to complementary and alternative therapies in the treatment of hypertension with anxiety or depression disorder and rank efficacy and safety, to provide a reference basis for the treatment of hypertension with anxiety or depression disorder.

Methods

This NMA will be implemented according to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) details [23]. The protocol was registered on the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY). No: INPLASY202120068.

Ethics and dissemination

This study is based on published data, and so it does not require ethical approval. The results of this NMA will be presented at scientific conferences and published in a peer-review journal.

Inclusion criteria

Type of study. The type of study is RCTs related to complementary and alternative therapies for EH complicated with anxiety or depression disorder, and the languages are Chinese and English.

Participants.

1. Patients who have diagnosed EH (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg, according to the diagnostic criteria of the Guidelines for Prevention and Control of Hypertension in 2010), with anxiety or depression disorder (according to the score of any validated scales).

2. It is not affected by the age, sex and region of the included patients.
Interventions. The control group was treated with or without conventional hypotensive drugs, at the same time, with or without anti-anxiety drugs or antidepressants. The treatment group was treated with complementary replacement therapies on the basis of the control group. The complementary replacement therapies include biological-based therapies, traditional Chinese medicine (TCM), acupuncture, massage, qigong, moxibustion, yoga, Chinese herbal medicines, music therapy, five-animal exercises, cognitive-behavioral therapy, relaxation training, tai chi, mindfulness meditation, and so on. They can also be used without conventional hypotensive drugs.

Outcomes. Primary outcomes include the change of SBP and DBP, the change in score of any validated scales, such as HAMA, HAMD, or SAS, SDS, which can assess the severity of anxiety or depression. The total efficacy rate, stationarity of hypotension, adverse effects, and TCM symptoms score are secondary outcomes.

Exclusion criteria

1. The type of study is non-RCTs;
2. The subjects included were diagnosed patients with secondary hypertension;
3. Patients without anxiety or depression;
4. Studies of unknown specific inclusion, exclusion criteria, and intervention measures;
5. There are obvious errors or the research data are unknown and cannot be extracted.

Databases and retrieval strategy

Chinese and English databases such as MEDLINE, PubMed, Embase, ClinicalTrials.gov, PsycINFO, Web of Science, Cochrane Library, Biosis, CNKI, Wanfang Database, Weipu Database and China Biology Medicine disc (CBMdisc) and so on will be searched by two independent researchers. RCTs, related to supplementation and replacement therapies of EH with anxiety or depression disorder, which were published from initial state to February 2021, will be collected in the form of computer retrieval. For the researches on incomplete information or some problems in the data, the corresponding author will be contacted to supplement the missing data as much as possible. At the same time, references of systematic review/meta-analysis as well as registered and ongoing trials will be traced. Take PubMed as an example, and the retrieval strategy is shown in Table 1.

Literature screening and data extraction

Literature screening: according to the retrieval strategy, the two researchers will check all the databases independently, and obtain all the studies related to this research. Then, by reading the title and abstract of studies, the studies which have nothing to do with the research will be excluded. Finally, we will read through the full text and screen the literature according to the inclusion and exclusion criteria mentioned above. The data will be imported into Endnote X9 software (Clarivate Analytics, Philadelphia, PA USA).

Data extraction: the chart of literature information will be drawn, and the two researchers will independently extract the information from the included researches. The level of agreement between the two researchers will be analysed by using the Kappa value [24], and if the value is greater than 0.60, it means substantial/almost perfect agreement. The extracted information will include: title, first author, race, gender, sources of participants, course of disease, publication time, country, journal, the support of the fund, the sources of the original literature, the number of cases in each group, inclusion and exclusion criteria, intervention
measures and implementation details, primary and secondary outcomes, follow-up period, method of randomized allocation, allocation concealment, blinding, loss of follow-up or withdrawal, security, ethics, etc.

**Assessment of trial quality**

The quality of literature will be scored according to the Jadad scale [25]. The Jadad score of the selected literature should be greater than or equal to 3. In case of disagreement, consult the third party to decide.

**Statistical analysis**

**Pairwise meta-analysis**

Stata 16.0 software will be used for statistical analysis. The ratio (OR) will be used as the index for the counting data, and the mean difference (MD) will be used for the measurement data.
The 95% confidence interval (95% CI) of each effect size will be given. A p-value <0.05 will be considered significant. We will combine with $I^2$ to quantitatively judge the size of heterogeneity.

**Network meta-analysis**

In this paper, the NMA is mainly based on the Bayesian theory to compare all the intervention measures and make a comprehensive evaluation at the same time. We will use $I^2$ or p-value to determine the types of model. If $I^2 > 50\%$ or $p \leq 0.05$, it indicates that there is heterogeneity, and we will use the random-effect model. If $I^2 \leq 50\%$ or $p > 0.05$, we will use the fixed-effect model. When there is heterogeneity, we will probe the sources of heterogeneity through sensitivity analysis or subgroup analysis. Markov chain Monte Carlo (MCMC) in WinBUGS1.4.3 is a method of the joint posterior distribution by constructing simulation parameters of Markov-chain. The steps are as follows: checking model logic and syntax, importing data, and compiling. In this study, three chains will be selected for simulation, with 40000 iterations and 10,000 annealing times. Gelman-Rubin-Brooks will be used to evaluate the convergence of the model. The higher the surface under the cumulative ranking curve values (SUCRA) indicates that the better the efficacy of the intervention [26]. And then the efficacy of the intervention measures included in the end will be ranked.

**Subgroup analysis and sensitivity analysis**

We will divided data into smaller units according to different design scheme, quality of literature, publishing year, etc., to make a further comparison.

After excluding the studies with abnormal results, the NMA will be carried out again, and the results are compared with the results of NMA, which does not exclude the studies with abnormal results, so as to probe the influence of the studies on the merger effect. The methods of sensitivity analysis include including or excluding those controversial studies on whether they meet the inclusion criteria, excluding studies with low quality, using different statistical methods to re-analyze data, and so on.

**Assessment of inconsistency**

IF and 95% CI will be calculated. The consistency of closed loops will be evaluated by 95% CI. We can also use the node splitting method to analyze each node of NMA and compare the difference of direct and indirect comparison. If P > 0.05, it means that there is no inconsistency.

**Evaluation of publication bias and evidence quality**

The included data will be tested by Begg’s and Egger’s funnel plot to evaluate whether there are publication bias and the effect of small sample size. If the included studies are concentrated near the midline and symmetrically distributed, it shows that the publication bias has little influence on this research. On the contrary, there will be publication bias.

The quality of evidence is divided into five levels—risk of bias, indirectness, inconsistency, imprecision, and publication bias—in NMA according to Grading of Recommendations Assessment, Development and Evaluation (GRADE) [27]. GRADE is used to evaluate the level of evidence and recommendation intensity.

**Discussion**

There is often a causal relationship between hypertension and psychological disorders. The prevalence rate of hypertension in patients with anxiety or depression is significantly higher...
than that in patients without anxiety or depression. On the contrary, the risk of anxiety and depression in patients with hypertension is significantly higher than that in patients without hypertension [28–30]. It plays a vital role in each other’s occurrence and development, which increases the difficulty in the treatment of hypertension [31, 32].

At present, It is difficult to achieve a satisfactory antihypertensive response by conventional hypotensive drugs for EH with anxiety or depression disorder and the side effects are obvious. Complementary and replacement therapies of EH with anxiety or depression disorder play an increasingly vital role. However, there are many kinds of complementary and replacement therapies and the efficacy is uneven, so it is difficult to choose the best scheme in the clinic. This will be the first NMA to systematically evaluate the efficacy and safety of different complementary and alternative therapies for EH with anxiety or depression disorder, and then we will rank them in order to get the best regimen, which can guide the clinical treatment.

We expect that this NMA will guide practice and research by providing reliable evidences of evidence-based medicine for treatment of EH with anxiety or depression disorder. Nevertheless, this study also has some limitations. For example, the use of different anxiety and depression scales in different studies may lead to publication bias.

Supporting information
S1 Checklist. PRISMA-P checklist.
(DOC)

Author Contributions
Conceptualization: Xueyan Han, Xinxin Liu, Qiming Zhang.
Formal analysis: Xueyan Han, Xinxin Liu.
Methodology: Fengxing Zhong, Yiguo Wang.
Project administration: Qiming Zhang.
Software: Xueyan Han, Fengxing Zhong.
Validation: Xinxin Liu, Yiguo Wang.
Writing – original draft: Xueyan Han, Xinxin Liu.
Writing – review & editing: Xueyan Han, Qiming Zhang.

References
1. Jefferson JW. Psychocardiology: meeting place of heart and mind. Psychosomatics. 1985; 26(11):841–842. https://doi.org/10.1016/S0033-3182(85)72774-0 PMID: 4080931.
2. Barquera S, Campos-Nonato I, Hernández-Barrera L, Villalpando S, Rodríguez-Gilabert C, Durazo-Arvizu R, et al. Hypertension in Mexican adults: results from the National Health and Nutrition Survey 2006. Salud Publica Mex. 2010; 52 Suppl 1:S63–S71. https://doi.org/10.1590/s0036-36342010000700010 PMID: 20585731.
3. Shinohara Y; OASIS Study Group. Factors affecting health-related quality of life assessed with the SF-36v2 health survey in outpatients with chronic-stage ischemic stroke in Japan—cross-sectional analysis of the OASIS study. Cerebrovasc Dis. 2010; 29(4):361–371. https://doi.org/10.1159/000281834 PMID: 20145390.
4. Rimar L, Rimar D. [Depression, myocardial infarction and the immune system—the chicken before the egg problem]. Harefuah. 2004; 143(1):73–78, 83. PMID: 14748293. Available from: https://pubmed.ncbi.nlm.nih.gov/14748293/.
5. Liu MY, Li N, Li WA, Khan H. Association between psychosocial stress and hypertension: a systematic review and meta-analysis. Neurol Res. 2017; 39(6):573–580. https://doi.org/10.1080/01616412.2017.1317904 PMID: 28415916.

6. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010; 303(20):2043–2050. https://doi.org/10.1001/jama.2010.650 PMID: 20501926.

7. Hamer M, Batterd GD, Stamatakis E, Kivimaki M. Hypertension awareness and psychological distress. Hypertension. 2010; 56(3):547–550. https://doi.org/10.1161/HYPERTENSIONAHA.110.153775 PMID: 20625078.

8. Almas A, Patel J, Ghorui U, Ali A, Edhi AI, Khan MA. Depression is linked to uncontrolled hypertension: a case-control study from Karachi, Pakistan. J Ment Health. 2014; 23(6):292–296. https://doi.org/10.3109/09638237.2014.924047 PMID: 24949520.

9. Cohen BE, Edmondson D, Kronish IM. State of the Art Review: Depression, Stress, Anxiety, and Cardiometabolic Disease. Am J Hypertens. 2015; 28(11):1295–1302. https://doi.org/10.1093/ajh/hpv047 Epub 2015 Apr 24. PMID: 25911639.

10. Kayano H, Kobayashi S, Matsui T, Fukuoka H, Toshida T, Sakai T, et al. Anxiety disorder is associated with nocturnal and early morning hypertension with or without morning surge: ambulatory blood pressure monitoring. Circ J. 2012; 76(7):1670–1677. https://doi.org/10.1253/circj.cj-11-1085 PMID: 22481104.

11. Meng L, Chen D, Yang Y, Zheng Y, Hui R. Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies. J Hypertens. 2012; 30(5):842–851. https://doi.org/10.1097/HJH.0b013e32835080b7 PMID: 22343537.

12. Lang UE, Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem. 2013; 31(6):761–777. https://doi.org/10.1159/000350094 PMID: 23735822.

13. Pan Y, Cai W, Cheng Q, Dong W, An T, Yan J. Association between anxiety and hypertension: a systematic review and meta-analysis of epidemiological studies. Neuropsychiatr Dis Treat. 2015; 11:1121–30. https://doi.org/10.2147/NDT.S77710 PMID: 25960656.

14. Ismail Z, Mohamad M, Isa MR, Fadzil MA, Yassin SM, Ma KT, et al. Factors associated with anxiety among elderly hypertensive in primary care setting. J Ment Health. 2015; 24(1):29–32. https://doi.org/10.3109/09638237.2014.971148 PMID: 25358109.

15. Hamer M, Steptoe A. Cortisol responses to mental stress and incident hypertension in healthy men and women. J Clin Endocrinol Metab. 2012; 97(1):E29–E34. https://doi.org/10.1210/jc.2011-2132 PMID: 22031509.

16. Ho AK, Thorpe CT, Pandhi N, Palta M, Smith MA, Johnson HM. Association of anxiety and depression with hypertensive control: a US multidisciplinary group practice observational study. J Hypertens. 2015; 33(11):2215–2222. https://doi.org/10.1097/HJH.0000000000000693 PMID: 26259121.

17. Gardner DM, Baldessarini RJ, Warach P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005; 172(13):1703–1711. https://doi.org/10.1503/cmaj.1041064 PMID: 15967975.

18. Licht CM, de Geus EJ, Seldenrijk A, van Hout HP, Zitman FG, van Dyck R, et al. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension. 2009; 53(4):631–638. https://doi.org/10.1161/HYPERTENSIONAHA.108.126698 PMID: 19237679.

19. Zou L, Yeung A, Li C, Wei GX, Chen KW, Kinser PA, et al. Effects of Meditative Movements on Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2018; 7(8):195. https://doi.org/10.3390/jcm7080195 PMID: 30071662.

20. Carek PJ, Laidstain SE, Carek SM. Exercise for the treatment of depression and anxiety. Int J Psychiatry Med. 2011; 41(1):15–28. https://doi.org/10.2190/PM.41.1.c PMID: 21495519.

21. Zhang XD, Cheng WQ, Wang YG, Zhang Z. [Clinical observation of modified Da Chaihu decoction in treating essential hypertension with anxiety]. Zhongguo Zhong Yao Za Zhi. 2017; 42(11):2181–2186. https://doi.org/10.19540/j.cnki.cjcm.2017.0099 PMID: 28822166.

22. Chen Y, Yang X, Wang L, Zhang X. A randomized controlled trial of the effects of brief mindfulness meditation on anxiety symptoms and systolic blood pressure in Chinese nursing students. Nurse Educ Today. 2013; 33(10):1166–1172. https://doi.org/10.1016/j.nedt.2012.11.014 PMID: 23260618.

23. Shamseeer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 350:g7647. https://doi.org/10.1136/bmj.g7647 PMID: 25558555.

24. Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther. 2005; 85(3):257–268. PMID: 15733050
25. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17(1):1–12. https://doi.org/10.1016/0197-2456(95)00134-4 PMID: 8721797.

26. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011; 64(2):163–171. https://doi.org/10.1016/j.jclinepi.2010.03.016 PMID: 20688472.

27. Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. GRADE Working Group. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014; 349:g5630. https://doi.org/10.1136/bmj.g5630 PMID: 25252733.

28. Stein DJ, Aguilar-Gaxiola S, Alonso J, Bruhaerts R, de Jonge P, Liu Z, et al. Associations between mental disorders and subsequent onset of hypertension. Gen Hosp Psychiatry. 2014; 36(2):142–149. https://doi.org/10.1016/j.genhosppsych.2013.11.002 PMID: 24342112.

29. Wang H, Zhang X, Zhang J, He Q, Hu R, Wang L, et al. Factors associated with prevalence, awareness, treatment and control of hypertension among adults in Southern China: a community-based, cross-sectional survey. PLoS One. 2013; 8(5):e62469. https://doi.org/10.1371/journal.pone.0062469 PMID: 23671599.

30. Rubio-Guerra AF, Rodríguez-Lopez L, Vargas-Ayala G, Huerta-Ramírez S, Serna DC, Lozano-Nuevo JJ. Depression increases the risk for uncontrolled hypertension. Exp Clin Cardiol. 2013 Winter; 18 (1):10–12. PMID: 24294029. Available from: https://pubmed.ncbi.nlm.nih.gov/24294029/.

31. Saxena T, Ali AO, Saxena M. Pathophysiology of essential hypertension: an update. Expert Rev CardiOvasc Ther. 2018; 16(12):879–887. https://doi.org/10.1080/14779072.2018.1540301 PMID: 30354851.

32. Ginty AT, Carroll D, Roseboom TJ, Phillips AC, de Rooij SR. Depression and anxiety are associated with a diagnosis of hypertension 5 years later in a cohort of late middle-aged men and women. J Hum Hypertens. 2013; 27(3):187–190. https://doi.org/10.1038/jhh.2012.18 PMID: 22592133.